# ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma

> **NCT07098364** · PHASE1,PHASE2 · RECRUITING · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 33 (estimated)

## Conditions studied

- Recurrent Diffuse Large B-Cell Lymphoma
- Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Recurrent Grade 3b Follicular Lymphoma
- Recurrent High-Grade B-Cell Lymphoma
- Recurrent Indolent B-Cell Non-Hodgkin Lymphoma
- Recurrent Primary Mediastinal Large B-Cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Refractory Grade 3b Follicular Lymphoma
- Refractory High-Grade B-Cell Lymphoma
- Refractory Indolent B-Cell Non-Hodgkin Lymphoma
- Refractory Primary Mediastinal Large B-Cell Lymphoma

## Interventions

- **BIOLOGICAL:** Vevoctadekin
- **PROCEDURE:** Bone Marrow Aspiration
- **PROCEDURE:** Bone Marrow Biopsy
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Echocardiography Test
- **PROCEDURE:** Leukapheresis
- **BIOLOGICAL:** Lisocabtagene Maraleucel
- **PROCEDURE:** Lumbar Puncture
- **PROCEDURE:** Lymphodepletion Therapy
- **PROCEDURE:** Multigated Acquisition Scan
- **PROCEDURE:** Positron Emission Tomography
- **PROCEDURE:** X-Ray Imaging
- **PROCEDURE:** Biospecimen Collection

## Key facts

- **NCT ID:** NCT07098364
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-27
- **Primary completion:** 2030-10-04
- **Final completion:** 2043-10-04
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2026-01-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07098364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07098364, "ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT07098364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*